Glial cell line derived neurotrophic factor market is anticipated to grow at a significant CAGR during the forecast period . Glial cell-derived neurotrophic factor (GDNF) is a protein encoded in humans by the GDNF gene. GDNF is a small protein that promotes the survival of several different types of neurons and communicates through GFR receptors, particularly GFR1. The major factor contributing to the growth of the market is the increasing prevalence of Parkinson’s disease (PD) across the globe.
To Request a Sample of our Report on Glial Cell Line Derived Neurotrophic Factor Market: https://www.omrglobal.com/request-sample/glial-cell-line-derived-neurotrophic-factor-market
According to the Parkinson Foundation, almost one million people are living with PD in the US which is expected to rise to 1.2 million in 2030. Additionally, approximately 60,000 Americans are diagnosed with PD each year and more than 10 million people are living with Parkinson’s disease globally. Further, Parkinson disease increases with age however, an estimated 4% of people with Parkinson disease are diagnosed before age 50. Moreover, the prevalence of Parkinson’s disease in men are 1.5 times as compared to women. Hence, the increasing prevalence of this disease is increasing the demand for glial cell line derived neurotrophic factors for treatment, which in turn, is driving the growth of the global glial cell line derived neurotrophic factor market. Some major players in the market include GlaxoSmithKline plc and Treeway BV, among others. The market players are contributing significantly to the growth of the market by the adoption of various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay competitive in the market.
Market Coverage
- The market number available for – 2021-2028
- Base year- 2021
- Forecast period- 2022-2028
Segment Covered-
- By Type
- By Application
Regions Covered-
- North America
- Europe
- Asia-Pacific
- Rest of the World
Competitive Landscape- GlaxoSmithKline Plc, and Treeway BV, among others
A full Report of Glial Cell Line Derived Neurotrophic Factor Market is Available @ https://www.omrglobal.com/industry-reports/glial-cell-line-derived-neurotrophic-factor-market
Glial Cell Line Derived Neurotrophic Factor Market Report by Segment
By Type
- GSK-812
- LAUR-301
- TW-002
- AMT-090
- Others
By Application
- Amyotrophic Lateral Sclerosis
- Brain Ischemia
- Parkinson’s Disease
- Retinal Degeneration
- Others
Glial Cell Line Derived Neurotrophic Factor Market Report by Region
North America
- United States
- Canada
Europe
- UK
- Germany
- Spain
- France
- Italy
- Rest of Europe
Asia-Pacific
- India
- China
- Japan
- South Korea
- Rest of APAC
Rest of the World
- Latin America
- Middle East & Africa
Reasons to buy from us –
- We cover more than 15 major industries, further segmented into more than 90 sectors.
- More than 120 countries are for analysis.
- Over 100+ paid data sources mined for investigation.
- Our expert research analysts answer all your questions before and after purchasing your report.
For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/glial-cell-line-derived-neurotrophic-factor-market
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404
